Literature DB >> 24136590

Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis.

F Dugay, X Le Goff, N Rioux-Leclerq, F Chesnel, F Jouan, C Henry, F Cabillic, G Verhoest, C Vigneau, Y Arlot-Bonnemains, M A Belaud-Rotureau.   

Abstract

The partition-defective 3 (PAR-3) protein is implicated in the development and maintenance of cell polarity and is associated with proteins that mediate the changes in cytoskeleton organization required for cell polarity establishment. In this work, we used two original primary cell lines (R-180 and R-305) derived from clear cell Renal Cell Carcinoma (ccRCC) surgical specimens of a patient with unfavorable clinical course (R-180 cells) and a patient with favorable prognosis (R-305 cells) to identify genetic and molecular features that may explain the survival difference of the two patients. The cytogenetic analysis of these cell lines revealed that the PARD3 gene was amplified only in the R-180 cell line that was derived from an aggressive ccRCC. PARD3 gene amplification was associated with overexpression of the encoded protein and altered cytoskeleton organization. Consistently, PARD3 knockdown in R-180 cells restored the cytoskeleton organization and reduced cell migration in comparison to non-transfected cells. Immunohistochemical analysis of ccRCC samples from a cohort of 96 patients with a follow-up of 6 years revealed that PAR-3 overexpression was correlated with poor survival. Our results suggest that PAR-3 has a role in the clinical aggressiveness of ccRCC, possibly by promoting cell migration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24136590     DOI: 10.1002/ijc.28548

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Expression of polarity genes in human cancer.

Authors:  Wan-Hsin Lin; Yan W Asmann; Panos Z Anastasiadis
Journal:  Cancer Inform       Date:  2015-03-30

2.  The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform.

Authors:  F Chesnel; P Hascoet; J P Gagné; A Couturier; F Jouan; G G Poirier; C Le Goff; C Vigneau; Y Danger; F Verite; X Le Goff; Y Arlot-Bonnemains
Journal:  Br J Cancer       Date:  2015-06-02       Impact factor: 7.640

3.  Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.

Authors:  Hiroe Nakamura; Kazunori Nagasaka; Kei Kawana; Ayumi Taguchi; Yuriko Uehara; Mitsuyo Yoshida; Masakazu Sato; Haruka Nishida; Asaha Fujimoto; Tomoko Inoue; Katsuyuki Adachi; Takeshi Nagamatsu; Takahide Arimoto; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii
Journal:  BMC Cancer       Date:  2016-11-17       Impact factor: 4.430

Review 4.  Cell polarity signaling in the plasticity of cancer cell invasiveness.

Authors:  Aneta Gandalovičová; Tomáš Vomastek; Daniel Rosel; Jan Brábek
Journal:  Oncotarget       Date:  2016-05-03

5.  High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.

Authors:  Songwei Li; Jian Huang; Fan Yang; Haiping Zeng; Yuyun Tong; Kejia Li
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

Review 6.  Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.

Authors:  Pauline Hascoet; Franck Chesnel; Cathy Le Goff; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Front Oncol       Date:  2015-10-27       Impact factor: 6.244

7.  Dual function of partitioning-defective 3 in the regulation of YAP phosphorylation and activation.

Authors:  Peng Zhang; Shuting Wang; Sai Wang; Jing Qiao; Lei Zhang; Zhe Zhang; Zhengjun Chen
Journal:  Cell Discov       Date:  2016-07-05       Impact factor: 10.849

8.  The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.

Authors:  Pauline Hascoet; Franck Chesnel; Florence Jouan; Cathy Le Goff; Anne Couturier; Eric Darrigrand; Fabrice Mahe; Nathalie Rioux-Leclercq; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Oncotarget       Date:  2017-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.